INTRODUCTION: The CCR5 chemokine receptor occurs in a wild-type (wt) and a nonfunctional deleted form (Δ32). Reports suggested that Chlamydia-induced reproductive tract pathology is attenuated in women bearing Δ32. The authors asked whether the mutation affects synovial prevalence and burden of Chlamydia trachomatis. METHODS: Polymerase chain reaction (PCR) defined CCR5 genotype in synovial tissue DNA from 218 individuals: 21 controls, 110 with reactive arthritis (ReA), 83 with undifferentiated oligoarthritis (UO), 4 with osteoarthritis (OA). Disease durations were 0.5 to 21 years. Additional PCR assays defined the presence of C trachomatis DNA. Bacterial load was assessed by real-time PCR in selected samples. RESULTS: Five controls were wt/Δ32, 16 were wt/wt; 2 of 21 controls (both wt/wt) were PCR positive for C trachomatis. Eighty-five (44%) patients with arthritis were PCR positive for C trachomatis (69 ReA and 16 UO). For patients with ReA, 14 (13%) had wt/Δ32, 10 (71%) of whom were PCR positive. Nineteen patients with UO (23%) were wt/Δ32, with 1 (1%) PCR positive. No differences existed for gender or other factors. One patient with OA had wt/Δ32. In ReA and UO samples, wt/Δ32 heterozygotes had a 5- to 10-fold higher bacterial burden than did wt/wt patients (P = 0.03), regardless of diagnosis. CONCLUSION: These results indicate that the wt/wt genotype is associated with attenuated synovial bacterial load compared with loads in wt/Δ32 patients. Although no alleles other than Δ32 were assessed, our data suggest that this allele provides little/no protection from ReA in patients infected with Chlamydia- but it may provide some protection in patients with UO. The basis of this possible differential effect of CCR5 genotype is under study.
INTRODUCTION: The CCR5 chemokine receptor occurs in a wild-type (wt) and a nonfunctional deleted form (Δ32). Reports suggested that Chlamydia-induced reproductive tract pathology is attenuated in women bearing Δ32. The authors asked whether the mutation affects synovial prevalence and burden of Chlamydia trachomatis. METHODS: Polymerase chain reaction (PCR) defined CCR5 genotype in synovial tissue DNA from 218 individuals: 21 controls, 110 with reactive arthritis (ReA), 83 with undifferentiated oligoarthritis (UO), 4 with osteoarthritis (OA). Disease durations were 0.5 to 21 years. Additional PCR assays defined the presence of C trachomatis DNA. Bacterial load was assessed by real-time PCR in selected samples. RESULTS: Five controls were wt/Δ32, 16 were wt/wt; 2 of 21 controls (both wt/wt) were PCR positive for C trachomatis. Eighty-five (44%) patients with arthritis were PCR positive for C trachomatis (69 ReA and 16 UO). For patients with ReA, 14 (13%) had wt/Δ32, 10 (71%) of whom were PCR positive. Nineteen patients with UO (23%) were wt/Δ32, with 1 (1%) PCR positive. No differences existed for gender or other factors. One patient with OA had wt/Δ32. In ReA and UO samples, wt/Δ32 heterozygotes had a 5- to 10-fold higher bacterial burden than did wt/wt patients (P = 0.03), regardless of diagnosis. CONCLUSION: These results indicate that the wt/wt genotype is associated with attenuated synovial bacterial load compared with loads in wt/Δ32 patients. Although no alleles other than Δ32 were assessed, our data suggest that this allele provides little/no protection from ReA in patients infected with Chlamydia- but it may provide some protection in patients with UO. The basis of this possible differential effect of CCR5 genotype is under study.
Authors: Erika L Barr; Sander Ouburg; Joseph U Igietseme; Servaas A Morré; Edith Okwandu; Francis O Eko; Godwin Ifere; Tesfaye Belay; Qing He; Deborah Lyn; Gift Nwankwo; James W Lillard; Carolyn M Black; Godwin A Ananaba Journal: J Microbiol Immunol Infect Date: 2005-08 Impact factor: 4.399
Authors: V Pokorny; F McQueen; S Yeoman; M Merriman; A Merriman; A Harrison; J Highton; L McLean Journal: Ann Rheum Dis Date: 2004-08-26 Impact factor: 19.103
Authors: H Amital; M Govoni; R Maya; P L Meroni; B Ori; Y Shoenfeld; A Tincani; F Trotta; P Sarzi-Puttini; F Atzeni Journal: Clin Exp Rheumatol Date: 2008 Jan-Feb Impact factor: 4.473
Authors: H J Girschick; L Guilherme; R D Inman; K Latsch; M Rihl; Y Sherer; Y Shoenfeld; H Zeidler; S Arienti; A Doria Journal: Clin Exp Rheumatol Date: 2008 Jan-Feb Impact factor: 4.473
Authors: I Scheibel; T Veit; A G Neves; L Souza; S Prezzi; S Machado; C Kohem; M Icarelli; R Xavier; J C Brenol; J A B Chies Journal: Scand J Rheumatol Date: 2008 Jan-Feb Impact factor: 3.641
Authors: William G Glass; David H McDermott; Jean K Lim; Sudkamon Lekhong; Shuk Fong Yu; William A Frank; John Pape; Ronald C Cheshier; Philip M Murphy Journal: J Exp Med Date: 2006-01-17 Impact factor: 14.307